Cancers, Vol. 12, Pages 2550: Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial
Cancers, Vol. 12, Pages 2550: Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial
Cancers doi: 10.3390/cancers12092550
Authors:
Henrik Suttmann
Jochen Gleissner
Andreas Huebner
Tim Mathes
Werner Baurecht
Katrin Krützfeldt
Hussein Sweiti
Susan Feyerabend
Residual androgen production causes tumor progression in metastatic, castration-resistant prostate cancer (mCRPC) patients. Abiraterone acetate (AA), a prodrug of abiraterone, is an oral CYP-17 inhibitor that blocks androgen production. It was hypothesized that adherence-enhancing measures (AEM) might be beneficial for mCRPC patients receiving abiraterone acetate plus prednisone (AA + P). This multicenter, prospective, 2-arm trial allocated mCRPC patients who were progressive after docetaxel-based chemotherapy or asymptomatic/mildly symptomatic after failure of an androgen deprivation therapy to Arm A (with AEM) or Arm B (without AEM) by center-based cluster-randomization. The primary objective was to assess the influence of AEM on discontinuation rates and medication adherence in mCRPC patients treated with AA + P. A total of 360 patients were allocated to Arm A, and 315 patients to Arm B. At month 3, the rate of treatment discontinuation, not due to disease progression or the start of new cancer therapy, was low in both arms (A: 9.0% vs. B: 7.3%, OR = 1.230). Few patient...
Source: Cancers - Category: Cancer & Oncology Authors: Henrik Suttmann Jochen Gleissner Andreas Huebner Tim Mathes Werner Baurecht Katrin Kr ützfeldt Hussein Sweiti Susan Feyerabend Tags: Article Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Docetaxel | Oral Cancer | Prednisone | Prostate Cancer | Taxotere